Xtant Medical Holdings, Inc. (XTNT) stock forecast & analysis
0.3920
NYSE American · USD
Up: +0.0080, +2.1%
1 analysis
- Open
- 0.3620
- Previous close
- 0.3840
- Day range
- 0.3460 – 0.4199
- 52-week range
- 0.2700 – 0.9500
- Volume (shares)
- 2.64M
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 140.29M
- P/E ratio
- Not available
- Dividend yield
- Not available
- Beta
- -0.14
- Market cap
- 54.99M
Market Scanner’s AI analysis of Xtant Medical Holdings, Inc. (XTNT), updated August 2026: XTNT's strategic dental market expansion via BioHorizons partnership contrasted with declining revenue and bearish technicals.
Summary
XTNT's strategic dental market expansion via BioHorizons partnership contrasted with declining revenue and bearish technicals.
Recent analyses for XTNT covered a new strategic partnership with BioHorizons to expand into the dental market, alongside discussions of the company's second-quarter 2026 earnings call. The reports also examined the company's financial performance, noting a significant year-over-year revenue decline and increasing debt, as well as technical indicators suggesting a bearish price trend.
XTNT news & sentiment
News reports highlighted Xtant's strategic expansion into the dental market via a partnership. Social media discussions and news coverage also referenced the company's recent earnings call, focusing on strategic growth and financial performance during that period.
XTNT technical picture
XTNT's price action traded below its 50-day and 200-day SMAs, indicating a bearish medium- and long-term trend, with short-term momentum also leaning bearish. Momentum indicators showed mixed signals, with MACD below its signal line but RSI in neutral territory and MFI indicating extremely strong buying pressure.
Fundamentals
The company's trailing twelve months revenue was $109,527,000 with a gross profit of $65,047,000. However, the trailing twelve months operating and profit margins were negative, and return on equity was also negative. Quarterly revenue growth year-over-year declined by 35%. Total debt stood at $26,012,000 with $9,870,000 in cash, and total debt increased by 41% from the previous quarter.
Factors discussed — upside
- Extremely strong buying pressure indicated by MFI
- Strategic expansion into the dental market through partnership with BioHorizons
- Current ratio of 2.162
Factors discussed — risks
- Stock price below 50-day and 200-day SMAs
- Short-term momentum leaning bearish
- Quarterly revenue growth year-over-year was -35%
- Total debt increased by 41% in the last quarter
- Operating margin and profit margin are negative
- Market expansion
- Financial performance
- Technical indicators
- Debt levels
Summary updated .
XTNT technical indicators
Common technical indicators for XTNT, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 0.40 | Price below |
| 10-day exponential moving average | 0.35 | Price above |
| Relative strength index (14-day) | 57.16 | Neutral |
| MACD line (12/26/9) | -0.0174 | Above its signal line |
| Bollinger bands (20-day, 2σ) | 0.25 – 0.46 | Price inside the bands |
Analyses
Recent XTNT.US analyses are locked — sign in to read them or generate a fresh one.
Frequently asked questions
- What is the bull case for Xtant Medical Holdings, Inc.?
- The bull case for XTNT centers on its strategic expansion into the dental market through an exclusive partnership with BioHorizons, aiming to broaden access to its allogeneic growth factor. Analyses also noted extremely strong buying pressure indicated by the Money Flow Index and a current ratio of 2.162.
- What are the risks for Xtant Medical Holdings, Inc.?
- Risks for XTNT highlighted in the analyses include the stock price trading below key moving averages, suggesting bearish medium- and long-term trends, and negative short-term momentum. The company reported a significant year-over-year revenue decline of 35%, negative operating and profit margins, and a substantial 41% increase in total debt over the last quarter.
- Is Xtant Medical Holdings, Inc. bullish or bearish?
- Recent AI analyses of Xtant Medical Holdings, Inc. examined factors on both sides. Discussed upside: The bull case for XTNT centers on its strategic expansion into the dental market through an exclusive partnership with BioHorizons, aiming to broaden access to its allogeneic growth factor. Analyses also noted extremely strong buying pressure indicated by the Money Flow Index and a current ratio of 2.162. Discussed risks: Risks for XTNT highlighted in the analyses include the stock price trading below key moving averages, suggesting bearish medium- and long-term trends, and negative short-term momentum. The company reported a significant year-over-year revenue decline of 35%, negative operating and profit margins, and a substantial 41% increase in total debt over the last quarter. These are descriptive observations, not a recommendation.
- What is the latest sentiment on Xtant Medical Holdings, Inc.?
- News reports highlighted Xtant's strategic expansion into the dental market via a partnership. Social media discussions and news coverage also referenced the company's recent earnings call, focusing on strategic growth and financial performance during that period.
- Bundles used
- gemini-low-v2
Run a fresh XTNT.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.
Or sign in to read every XTNT.US report already in the library